Repurposed drug against COVID-19: nanomedicine as an approach for finding new hope in old medicines

Author:

Ahmad Mohammad ZakiORCID,Ahmad JavedORCID,Aslam MohammedORCID,Khan Mohammad Ahmed,Alasmary Mohammed Yahia,Abdel-Wahab Basel AORCID

Abstract

Abstract The coronavirus disease 2019 (COVID-19) has become a threat to global public health. It is caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) and has triggered over 17 lakh causalities worldwide. Regrettably, no drug or vaccine has been validated for the treatment of COVID-19 and standard treatment for COVID-19 is currently unavailable. Most of the therapeutics moieties which were originally intended for the other disease are now being evaluated for the potential to be effective against COVID-19 (re-purpose). Nanomedicine has emerged as one of the most promising technologies in the field of drug delivery with the potential to deal with various diseases efficiently. It has addressed the limitations of traditional repurposed antiviral drugs including solubility and toxicity. It has also imparted enhanced potency and selectivity to antivirals towards viral cells. This review emphasizes the scope of repositioning of traditional therapeutic approaches, in addition to the fruitfulness of nanomedicine against COVID-19.

Publisher

IOP Publishing

Subject

General Medicine

Reference155 articles.

1. COVID-19: what has been learned and to be learned about the novel coronavirus disease;Yi;Int J Biol Sci,2020

2. The novel coronavirus outbreak in Wuhan, China;Zhu;Glob Health Res. Policy,2020

3. COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses;Shereen;J. Adv. Res.,2020

4. Liver and Kidney Injuries in COVID-19 and Their Effects on Drug Therapy; a Letter to Editor;Rismanbaf;Arch. Acad. Emerg. Med.,2020

5. COVID-19 can affect the heart;Topol;Science,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3